E-cigarette and vape uses more prone to infection

Industry InsightInnovation
Jul.22.2022
E-cigarette and vape uses more prone to infection

Rima, a 27-year-old Saudi woman, holds her electronic cigarette as she vapes at a coffee shop in downtown Riyadh, a sign of the changing times in Saudi Arabia - Copyright AFP/File JOHN THYS

Read more: https://www.digitaljournal.com/tech-science/e-cigarette-and-vape-uses-more-prone-to-infection/article#ixzz7ZkXgRHcoUsers of nicotine products are more susceptible to contracting an infection. One research study identified an abundance of Porphyromonas (a genus of Gram-negative bacteria implicated in periodontal disease) and Veillonella (a different group of Gram-negatives associated with cases of osteomyelitis and endocarditis) in higher levels among vapers, suggesting that vaping alters the oral microbiome. The oral microbiome has an established relationship to overall health and it is the second and most diverse microbiota next to the gut, home to over 1,000 species of microbes.

 

Disruptions to this community can lead to health implications. Of particular concern is the bacterium Porphyromonas gingivalis. Enzymes produced by the bacterium can attack collagen.
 

Periodontal, or gum, disease is one of the most common infectious diseases worldwide. In its more severe forms, such as periodontitis, the condition causes loss of the bone that supports the teeth. In addition to gum disease, the bacterium has been linked to rheumatoid arthritis.

 

Ecosystem stability can be affected by two types of disturbances: long-term influences or “presses” and short-term effects or “pulses”. Furthermore, the researchers discovered that interleukin (IL)-6 and IL-1?, a pro-inflammatory cytokines which indicate inflammatory responses, were highly elevated in e-cigarette users when compared with non-users. In particular, epithelial cell-exposed e-cigarette aerosols were more susceptible for infection. This led to the assessment that e-cigarette users are more prone to infection. This occurs because alterations to the microbial landscape, which accompanies higher levels of proteins in vapers’ mouths, signals that the immune system is more likely to activate and produce inflammation. In turn this exponentially increases the likelihood for disease.

 

Additionally, sequencing based studies have shown that certain species of bacteria (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa) are more strongly associated with the development of a
lung community skewed towards loss of diversity. Concerningly, these organisms are associated with declining lung function. It appears that e-cigarette vapor can change the way the bacteria grow, by increasing volume and the area covered by the bacteria, which can lead to infections if untreated.
 

The association between the oral cavity and disease is complex, with the pathogenicity of chronic periodontal disease a factor of the complex interaction of microbial pathogens, host immune response, and genetic and environmental factors. The drawing in of chemical vapor adds to the environmental complexity and appears to be a microbiome altering factor. However, what stands out from research is the general trend that the majority of the metagenome in e-cigarette users was shared by more than the majority of users, which contrasts with smokers and non-smokers, who do not tend to share their bacterial and fungal composition.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
China’s Shanghai Tobacco Group Launches CNY 10.98 Million (Approximately US$1.53 Million) Procurement for Heated Tobacco Production Utility Equipment
China’s Shanghai Tobacco Group Launches CNY 10.98 Million (Approximately US$1.53 Million) Procurement for Heated Tobacco Production Utility Equipment
Shanghai Tobacco Group Co., Ltd., a tobacco manufacturing company under China National Tobacco Corporation (CNTC), has launched a public tender for heated tobacco products (HTPs) production utility equipment at its Shanghai Cigarette Factory. The project is valued at CNY 10.98 million and covers six combined air-conditioning units, electrical cabinets and control systems for production facilities. The procurement includes equipment design, supply, installation, commissioning and related training services.
Aug.07